Matches in Wikidata for { <http://www.wikidata.org/entity/Q66081304> ?p ?o ?g. }
Showing items 1 to 47 of
47
with 100 items per page.
- Q66081304 description "clinical trial" @default.
- Q66081304 description "ensayu clínicu" @default.
- Q66081304 description "klinisch onderzoek" @default.
- Q66081304 description "клінічне випробування" @default.
- Q66081304 name "Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma" @default.
- Q66081304 name "Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma" @default.
- Q66081304 type Item @default.
- Q66081304 label "Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma" @default.
- Q66081304 label "Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma" @default.
- Q66081304 prefLabel "Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma" @default.
- Q66081304 prefLabel "Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma" @default.
- Q66081304 P1050 Q66081304-651E3ECB-A8CC-47EE-B716-9FF2C0CA6990 @default.
- Q66081304 P1050 Q66081304-D5728A89-F59D-46C8-BA1E-7F66430A522D @default.
- Q66081304 P1132 Q66081304-7F4501D3-DBA2-487B-A940-A6589821E1CA @default.
- Q66081304 P1476 Q66081304-CA48628F-86BA-4134-8554-FD05A49C6656 @default.
- Q66081304 P17 Q66081304-143928AD-104C-450C-9DB6-7D3D728BEF6F @default.
- Q66081304 P17 Q66081304-3CA46DF5-CB58-4B1C-B2E7-575385D73444 @default.
- Q66081304 P17 Q66081304-49E0A818-7EE4-45D3-A4BF-C0ABBE6EC8B3 @default.
- Q66081304 P17 Q66081304-91CA3863-0189-4F2E-948B-BDEC90B4E747 @default.
- Q66081304 P17 Q66081304-F853EA88-5B6B-4A17-94C8-909D4B8610DA @default.
- Q66081304 P1813 Q66081304-DBCE7D47-FAEB-4A7D-88DC-80C0A5686735 @default.
- Q66081304 P2899 Q66081304-18B7A038-E60D-4BB4-BA5A-2676C3A2FD14 @default.
- Q66081304 P3098 Q66081304-4245580E-4BF9-4DE7-A41B-133297508803 @default.
- Q66081304 P31 Q66081304-D098EC91-BA66-43EA-908A-2D8AC2D343A0 @default.
- Q66081304 P4135 Q66081304-6A60C1A2-4F43-4C41-8326-CBD29499087C @default.
- Q66081304 P580 Q66081304-1754E4D7-9786-4A36-AB74-24FEE5BDFFEF @default.
- Q66081304 P582 Q66081304-75A331F3-5577-4EB6-8B8A-6CE3D6D48A96 @default.
- Q66081304 P6099 Q66081304-9DDF4E74-5B34-4945-8FCE-8835C0C9ED3E @default.
- Q66081304 P8363 Q66081304-22452020-85CF-4BE7-9D2B-020AF5512899 @default.
- Q66081304 P1050 Q208414 @default.
- Q66081304 P1050 Q29496 @default.
- Q66081304 P1132 "+289" @default.
- Q66081304 P1476 "Phase 2 Study of the Combination of Ibrutinib Plus Venetoclax in Subjects With Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma" @default.
- Q66081304 P17 Q29 @default.
- Q66081304 P17 Q30 @default.
- Q66081304 P17 Q38 @default.
- Q66081304 P17 Q408 @default.
- Q66081304 P17 Q664 @default.
- Q66081304 P1813 "CAPTIVATE" @default.
- Q66081304 P2899 "+18" @default.
- Q66081304 P3098 "NCT02910583" @default.
- Q66081304 P31 Q30612 @default.
- Q66081304 P4135 "+70" @default.
- Q66081304 P580 "2016-10-01T00:00:00Z" @default.
- Q66081304 P582 "2020-12-01T00:00:00Z" @default.
- Q66081304 P6099 Q42824440 @default.
- Q66081304 P8363 Q78089383 @default.